What makes a compliant Phase III and pre-launch patient advocacy strategy?. Issue 1 (1st January 2016)

• Record Type: Journal Article
• Authors: Hicks, Nick; Allan, Keith; Thalheim, Christoph; Woods, Paul
• Is Part Of: Journal of market access & health policy. Volume 4:Issue 1(2016)
• Publication Date: 2016-01-01
• Subjects: pharmaceutical industry -- patient advisory group -- transparency -- compliance -- ethics -- reputation; Medical policy -- Periodicals; Medical policy -- Economic aspects -- Periodicals; International trade -- Environmental aspects -- Periodicals; Health Policy -- economics; Technology Assessment, Biomedical; Marketing of Health Services; International trade -- Environmental aspects; Medical policy; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 362.1
• DOI: 10.3402/jmahp.v4.33177
• Languages: English
• ISSNs: 2001-6689

Abstract

Abstract : Background: A key task for the pharmaceutical industry is to understand the compliance implications of engaging with a patient advocacy group (PAG). This presents challenges for the industry to negotiate the ethical and reputational issues that can arise when working with a PAG. Objective: To gain the views of pharmaceutical industry executives on future compliance challenges when working with PAGs. Study design: We conducted two surveys among two sets of industry executives: one group focussed on market access roles and the other focussed on non-market access roles. Results: Transparency was identified as the biggest challenge, followed by project rationale and then by project ownership. Conclusion: We explore how this can be overcome and make recommendations on how best to work compliantly with PAGs.